Everything we've seen

1. ?Nov 13, 2:15 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   PODD is up 2.38% intraday with no attributable headline, suggesting this is likely technical or flow-driven buying rather than a news catalyst. The move is meaningful in magnitude — real size was involved. However, several factors temper enthusiasm: (1) 90 minutes remaining is enough time for continuation but also enough for a fade if momentum stalls; (2) the macro context shows a compressed yield curve (T10Y2Y at 2.0σ below trend), which is modestly risk-off and tends to favor defensives over growth-oriented medtech names like PODD; (3) no news catalyst means the move could be a morning gap or block trade that has already played out, with no fresh catalyst to sustain it into the close. With no reversal signal visible and the move still holding near session highs, the base rate for continuation is marginally positive. Assigning 0.52 — a slight lean toward continuation given the magnitude of the move and time remaining, but no strong conviction given macro headwinds and absence of a news driver.

2. !Nov 13, 2:15 PMsignalseverity 0.02

   Agent 7 — Day Trader — day_trade_skipped

   PODD is up 2.38% intraday with no attributable headline, suggesting this is likely technical or flow-driven buying rather than a news catalyst. The move is meaningful in magnitude — real size was involved. However, several factors temper enthusiasm: (1) 90 minutes remaining is enough time for continuation but also enough for a fade if momentum stalls; (2) the macro context shows a compressed yield curve (T10Y2Y at 2.0σ below trend), which is modestly risk-off and tends to favor defensives over growth-oriented medtech names like PODD; (3) no news catalyst means the move could be a morning gap or block trade that has already played out, with no fresh catalyst to sustain it into the close. With no reversal signal visible and the move still holding near session highs, the base rate for continuation is marginally positive. Assigning 0.52 — a slight lean toward continuation given the magnitude of the move and time remaining, but no strong conviction given macro headwinds and absence of a news driver.

3. ?Nov 12, 2:36 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

4. !Nov 12, 2:36 PMsignalseverity 0.11

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

5. ?Nov 12, 10:20 AMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

6. !Nov 12, 10:20 AMsignalseverity 0.11

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

7. ?Nov 12, 9:20 AMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

8. !Nov 12, 9:20 AMsignalseverity 0.11

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

9. ❖Nov 12, 8:35 AMnewsvia finnhub

   Insulet (PODD) Just Overtook the 20-Day Moving Average

   Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

10. ❖Nov 11, 4:17 PMnewsvia finnhub

    Is DexCom Stock Cheaper Now That Its Multiple Has Fallen?

    For questions about this article or underlying research, email help@trefis.com.

11. ?Nov 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

12. !Nov 11, 2:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

13. ?Nov 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

14. !Nov 11, 1:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

15. ?Nov 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

16. !Nov 11, 12:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

17. ?Nov 11, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

18. !Nov 11, 10:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

19. ?Nov 11, 9:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

20. !Nov 11, 9:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

21. ❖Nov 11, 6:39 AMnewsvia finnhub

    Insulet: Rivals Are Building Patch Pumps, But Insulet Already Owns The Pharmacy Counter

    The bull case for Insulet: its sub-median valuation looks attractive as 74.2% gross margins and 21%-22% 2026 revenue growth show operating leverage.

22. ❖Nov 10, 2:42 PMnewsvia finnhub

    Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

    Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

23. ?Nov 10, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

24. !Nov 10, 2:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

25. ?Nov 10, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

26. !Nov 10, 1:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

27. ?Nov 10, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

28. !Nov 10, 12:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

29. ?Nov 10, 11:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

30. !Nov 10, 11:20 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

31. ?Nov 10, 11:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down ~1.91% today with no attributable news catalyst visible. The move is meaningful but sits at the lower end of the 2-5% 'conviction' range, making it harder to classify as a strong directional flow signal. With 280 minutes remaining (essentially the full afternoon session), there is ample time for continuation — but also ample time for mean reversion. The macro context (DFF elevated ~2.0σ above trend) is modestly negative for growth/medtech names like PODD insofar as higher rates pressure high-multiple healthcare device stocks, providing a mild tailwind to the downside thesis. However, without a specific catalyst driving the sell-off and no volume data confirming institutional distribution, this reads as ordinary drift rather than a high-conviction breakdown. No reversal signals are evident, so I won't fade it, but the evidence doesn't support a high-confidence continuation call either. Setting continuation probability at exactly 0.5 — the threshold for a marginal trade entry with tight downside stop of -1.5% providing bounded risk.

32. !Nov 10, 11:05 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down ~1.91% today with no attributable news catalyst visible. The move is meaningful but sits at the lower end of the 2-5% 'conviction' range, making it harder to classify as a strong directional flow signal. With 280 minutes remaining (essentially the full afternoon session), there is ample time for continuation — but also ample time for mean reversion. The macro context (DFF elevated ~2.0σ above trend) is modestly negative for growth/medtech names like PODD insofar as higher rates pressure high-multiple healthcare device stocks, providing a mild tailwind to the downside thesis. However, without a specific catalyst driving the sell-off and no volume data confirming institutional distribution, this reads as ordinary drift rather than a high-conviction breakdown. No reversal signals are evident, so I won't fade it, but the evidence doesn't support a high-confidence continuation call either. Setting continuation probability at exactly 0.5 — the threshold for a marginal trade entry with tight downside stop of -1.5% providing bounded risk.

33. ?Nov 10, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down 1.70% today, which is a moderate but not particularly strong intraday move. There are no recent headlines to explain the move or suggest a catalyst that would sustain it. The macro context (elevated fed funds rate ~2σ above trend) is modestly negative for growth/medtech names like PODD, as higher rates compress valuations on longer-duration equities, providing a mild tailwind for continuation of the downside. However, the move is below the 2% threshold that would signal strong conviction, and with 365 minutes remaining (essentially a full trading day ahead), there is ample time for either continuation or mean reversion. The absence of a clear catalyst cuts both ways — no panic seller identified, but also no news-driven buyers stepping in. With no reversal pattern evident and macro context mildly supportive of the downside for a growth medical device name, I lean marginally toward continuation but with low conviction. Probability sits at the floor of the continuation range.

34. !Nov 10, 9:40 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down 1.70% today, which is a moderate but not particularly strong intraday move. There are no recent headlines to explain the move or suggest a catalyst that would sustain it. The macro context (elevated fed funds rate ~2σ above trend) is modestly negative for growth/medtech names like PODD, as higher rates compress valuations on longer-duration equities, providing a mild tailwind for continuation of the downside. However, the move is below the 2% threshold that would signal strong conviction, and with 365 minutes remaining (essentially a full trading day ahead), there is ample time for either continuation or mean reversion. The absence of a clear catalyst cuts both ways — no panic seller identified, but also no news-driven buyers stepping in. With no reversal pattern evident and macro context mildly supportive of the downside for a growth medical device name, I lean marginally toward continuation but with low conviction. Probability sits at the floor of the continuation range.

35. ?Nov 9, 2:46 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is up 2.27% today with no attributable headline, suggesting institutional flow or technical breakout driving the move. With 60 minutes remaining, there is some time for continuation but the window is narrowing. The macro context (elevated mortgage rates) is not particularly relevant to PODD (a medical device/insulin pump company), so no sector headwind applies. Absence of news does not disqualify the move — large intraday moves in medical devices often reflect sector rotation or fund activity that can persist into the close. However, with only 60 minutes left and no clear catalyst to point to, there is some risk of late-day profit-taking or fade. The move magnitude (2.27%) is meaningful but not extreme, suggesting it may not have exhausted itself. Leaning modestly toward continuation with no strong reason to fade, but conviction is limited by the short time window and lack of confirming news.

36. !Nov 9, 2:46 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    PODD is up 2.27% today with no attributable headline, suggesting institutional flow or technical breakout driving the move. With 60 minutes remaining, there is some time for continuation but the window is narrowing. The macro context (elevated mortgage rates) is not particularly relevant to PODD (a medical device/insulin pump company), so no sector headwind applies. Absence of news does not disqualify the move — large intraday moves in medical devices often reflect sector rotation or fund activity that can persist into the close. However, with only 60 minutes left and no clear catalyst to point to, there is some risk of late-day profit-taking or fade. The move magnitude (2.27%) is meaningful but not extreme, suggesting it may not have exhausted itself. Leaning modestly toward continuation with no strong reason to fade, but conviction is limited by the short time window and lack of confirming news.

37. ?Nov 9, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

38. !Nov 9, 12:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

39. ?Nov 9, 11:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

40. !Nov 9, 11:20 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

41. ?Nov 9, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

42. !Nov 9, 10:21 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

43. ?Nov 9, 9:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

44. !Nov 9, 9:20 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

45. ❖Nov 9, 7:00 AMnewsvia finnhub

    For World Diabetes Day, Insulet Launches "Give Yourself the Freedom to" Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being

    ACTON, Mass., November 09, 2026--In recognition of World Diabetes Day on November 14, 2026, Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its "Give Yourself the Freedom to" campaign designed to raise awareness of the often overlooked emotional and mental demands of living with diabetes and encourage people living with diabetes to prioritize their own well-being.

46. ?Nov 9, 6:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

47. !Nov 9, 6:01 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

48. ❖Nov 9, 5:11 AMnewsvia finnhub

    Truist Securities Reiterates Hold on Insulet, Raises Price Target to $160

    Truist Securities analyst Richard Newitter reiterates Insulet (NASDAQ:PODD) with a Hold and raises the price target from $153 to $160.

49. ❖Nov 7, 7:49 AMnewsvia finnhub

    What Is Behind The Move In DexCom Stock?

    For questions about this article or underlying research, email help@trefis.com.

50. ✓Nov 6, 7:32 PMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    PODD (Insulet Corporation) is a med-tech leader in insulin delivery (OmniPod), a business largely insulated from housing/mortgage macro headwinds — the elevated mortgage rate environment flagged in macro context is not a material concern for this sector. The 13% drawdown from the 30-day high lacks any visible negative catalyst in the news or SEC filings; the recent 10-Q and 8-K filings carry no reported negative metrics, suggesting the drop may be technical or sector rotation-driven rather than fundamental deterioration. Med-tech names with durable recurring revenue and strong competitive positioning tend to mean-revert after non-fundamental pullbacks of this magnitude.

51. ❖Nov 6, 3:06 PMnewsvia finnhub

    S&P 500 Top Movers: Nov. 6, 2026 Gainers and Losers

    S&P 500 top movers for Nov. 6, 2026: Coherent, Airbnb, AppLovin, NRG and Vistra led gainers, while Axon and Microchip led losers.

52. ?Nov 6, 2:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down -6.58% with 65 minutes remaining — a significant move that reflects real institutional selling pressure. No headlines are available to explain the drop, but absence of news does not negate the momentum signal; large moves without obvious catalysts often reflect pre-positioned institutional flows or sector rotation that persists into the close. The macro context (elevated mortgage rates) is not directly relevant to PODD (a medical device/insulin pump company), so there is no sector-level tailwind or headwind to consider from that angle. With 65 minutes remaining, there is meaningful time for continuation, but the move has already been substantial (-6.58%), which raises the probability that some mean-reversion or profit-taking by intraday shorts could emerge. Weighing the momentum signal (favors continuation) against the late-session timing and the magnitude of the existing move (which slightly increases fade risk), this is a marginal continuation setup. Probability set at 0.52 — slight lean toward continued downside but without high conviction.

53. !Nov 6, 2:40 PMsignalseverity -0.07

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down -6.58% with 65 minutes remaining — a significant move that reflects real institutional selling pressure. No headlines are available to explain the drop, but absence of news does not negate the momentum signal; large moves without obvious catalysts often reflect pre-positioned institutional flows or sector rotation that persists into the close. The macro context (elevated mortgage rates) is not directly relevant to PODD (a medical device/insulin pump company), so there is no sector-level tailwind or headwind to consider from that angle. With 65 minutes remaining, there is meaningful time for continuation, but the move has already been substantial (-6.58%), which raises the probability that some mean-reversion or profit-taking by intraday shorts could emerge. Weighing the momentum signal (favors continuation) against the late-session timing and the magnitude of the existing move (which slightly increases fade risk), this is a marginal continuation setup. Probability set at 0.52 — slight lean toward continued downside but without high conviction.

54. ?Nov 6, 1:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

55. !Nov 6, 1:21 PMsignalseverity 0.15

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

56. ❖Nov 6, 12:36 PMnewsvia finnhub

    S&P 500 Top Movers: Gainers and Losers on Nov. 6, 2026

    S&P 500 top movers for Nov. 6, 2026: LRCX led gainers at 12.66%, while AXON led decliners at -17.99%. See the session's notable index moves.

57. ?Nov 6, 12:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

58. !Nov 6, 12:21 PMsignalseverity 0.15

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

59. ?Nov 6, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

60. !Nov 6, 11:21 AMsignalseverity 0.14

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

61. ❖Nov 6, 10:36 AMnewsvia finnhub

    S&P 500 Gap-Down Stocks in Today's Session

    S&P 500 gap-down stocks including AXON, MCHP and CHTR are listed with gap size and today's session moves.

62. ?Nov 6, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

63. !Nov 6, 10:21 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD (Insulet Corp) is down 13.3% from its 30-day high, just below the 15% mean-reversion threshold. No hard veto conditions are triggered: no imminent earnings, no fundamental deterioration visible in the 10-Q/8-K filings (metrics are empty, no red flags), and no going-concern language. The Health Care sector is a strong relative outperformer (rank 3 of 11, +13.35pts vs SPY over 30 days), which is a double-edged signal — it means the dip is likely idiosyncratic to PODD rather than sector-wide, scoring a negative signal. Net signal score: No cluster buys (0), no options flow data (0), sector outperforming while PODD drops idiosyncratically (-1), drop is 13.3% not ≥15% (0), no earnings in window (+1), macro is mixed with 10Y at 4.90% above the 4.5% headwind threshold for a growth/duration-sensitive MedTech name (-1), VIX at 39th percentile is neutral (0). Net score: -1, which per the framework suggests skipping.

64. ✓Nov 6, 10:21 AMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    PODD (Insulet Corporation) is a med-tech leader in insulin delivery (OmniPod), operating in a structurally growing diabetes-care market with no confirmed fundamental impairment evident in the available data — the 10-Q and 8-K filed 2026-11-04 show no disclosed metrics suggesting deterioration. The Health Care sector is a strong relative outperformer (rank 3/11, +13.35pts vs SPY over 30 days), suggesting the ~13.3% drop from the 30-day high is likely idiosyncratic rather than sector-driven, which warrants some caution but also implies a potential mean-reversion opportunity if the catalyst is temporary. Broad market tone today is constructive (SPY +1.05%, QQQ +2.15%, VXX -7.30%), and VIX at the 39th percentile reflects a benign macro volatility environment.

65. ❖Nov 6, 7:13 AMnewsvia finnhub

    Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165

    Barclays analyst Christopher Pasquale maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $150 to $165.

66. ❖Nov 5, 6:20 PMnewsvia finnhub

    Insulet (PODD) Stock May Be 36% Undervalued Despite $1b Buyback

    Insulet has had a rough stretch on the market over the past year, yet the share price now sits against a backdrop of fresh buyback plans and stronger recent trading. That mix puts the focus squarely on one issue for investors who care about valuation: whether the current market value can be explained by the cash the business is expected to generate. Over the past 12 months, Insulet shares have fallen 51.7%, which puts a lot of past optimism about the business under review and makes the...

67. ❖Nov 5, 3:41 PMnewsvia finnhub

    UBS Maintains Neutral on Insulet, Raises Price Target to $171

    UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $171.

68. ❖Nov 5, 2:31 PMnewsvia finnhub

    JP Morgan Maintains Neutral on Insulet, Raises Price Target to $170

    JP Morgan analyst Robbie Marcus maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $152 to $170.

69. ?Nov 5, 1:41 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down ~7% intraday, a significant move reflecting real institutional selling pressure. No headlines are present, but the magnitude of the drop suggests either an earnings miss, guidance cut, or large block liquidation — all of which tend to see continuation as other holders reassess positions. With 125 minutes remaining, there is meaningful time for the move to extend further. The macro context (DFF elevated 2.1σ above trend, hawkish rate environment) is modestly negative for high-multiple med-tech names like PODD, which trades at a premium valuation and is sensitive to discount rate pressure. No reversal signals are evident from the data provided. The absence of a bounce catalyst and the size of the initial move lean toward continuation rather than a sharp recovery. Probability is set conservatively at 0.54 — above the action threshold — given the lack of volume confirmation data and the possibility that the worst of the selling is already done after a 7% flush.

70. !Nov 5, 1:41 PMsignalseverity -0.07

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down ~7% intraday, a significant move reflecting real institutional selling pressure. No headlines are present, but the magnitude of the drop suggests either an earnings miss, guidance cut, or large block liquidation — all of which tend to see continuation as other holders reassess positions. With 125 minutes remaining, there is meaningful time for the move to extend further. The macro context (DFF elevated 2.1σ above trend, hawkish rate environment) is modestly negative for high-multiple med-tech names like PODD, which trades at a premium valuation and is sensitive to discount rate pressure. No reversal signals are evident from the data provided. The absence of a bounce catalyst and the size of the initial move lean toward continuation rather than a sharp recovery. Probability is set conservatively at 0.54 — above the action threshold — given the lack of volume confirmation data and the possibility that the worst of the selling is already done after a 7% flush.

71. ❖Nov 5, 1:07 PMnewsvia finnhub

    Citigroup Maintains Neutral on Insulet, Raises Price Target to $170

    Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $170.

72. ?Nov 5, 11:20 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down ~4.93% today with no headline catalyst visible, suggesting either a sector rotation, options-related flow, or earnings-adjacent positioning. The move is meaningful in size and implies real selling conviction. However, several factors temper the continuation probability: (1) With 265 minutes remaining there is ample time, but a move of this magnitude without news often attracts mean-reversion buyers in the afternoon session as algos and value-oriented participants step in near support. (2) The macro context (elevated DFF at 3.88, 2.1σ above trend) is modestly hawkish and reactive to financials/money-market sectors — not directly negative for a medical device name like PODD, so no macro tailwind for continued selling. (3) Absence of news cuts both ways per instructions, but for a device-sector name a 5% drop without a catalyst can represent a flush that is closer to completion than to continuation. (4) No reversal signal is evident yet, so there is no active reason to expect a fade. On balance, momentum slightly favors continuation into the close but conviction is modest — this is a borderline setup resolved in favor of the trade direction per system rules.

73. !Nov 5, 11:20 AMsignalseverity -0.05

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down ~4.93% today with no headline catalyst visible, suggesting either a sector rotation, options-related flow, or earnings-adjacent positioning. The move is meaningful in size and implies real selling conviction. However, several factors temper the continuation probability: (1) With 265 minutes remaining there is ample time, but a move of this magnitude without news often attracts mean-reversion buyers in the afternoon session as algos and value-oriented participants step in near support. (2) The macro context (elevated DFF at 3.88, 2.1σ above trend) is modestly hawkish and reactive to financials/money-market sectors — not directly negative for a medical device name like PODD, so no macro tailwind for continued selling. (3) Absence of news cuts both ways per instructions, but for a device-sector name a 5% drop without a catalyst can represent a flush that is closer to completion than to continuation. (4) No reversal signal is evident yet, so there is no active reason to expect a fade. On balance, momentum slightly favors continuation into the close but conviction is modest — this is a borderline setup resolved in favor of the trade direction per system rules.

74. ❖Nov 5, 11:01 AMnewsvia finnhub

    Leerink Partners Maintains Market Perform on Insulet, Raises Price Target to $167

    Leerink Partners analyst Mike Kratky maintains Insulet (NASDAQ:PODD) with a Market Perform and raises the price target from $143 to $167.

75. ❖Nov 5, 10:29 AMnewsvia finnhub

    RBC Capital Maintains Outperform on Insulet, Raises Price Target to $180

    RBC Capital analyst Kendall Au maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $160 to $180.

76. ❖Nov 5, 8:22 AMnewsvia finnhub

    Bernstein Maintains Outperform on Insulet, Raises Price Target to $200

    Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $175 to $200.

77. ❖Nov 5, 6:16 AMnewsvia finnhub

    Wells Fargo Maintains Equal-Weight on Insulet, Raises Price Target to $172

    Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $144 to $172.

78. ❖Nov 5, 12:24 AMnewsvia finnhub

    Insulet Stock What’s Changed After Earnings Beat

    Insulet reported third quarter 2026 revenue of US$842 million and net income of US$141.1 million, with earnings per share of US$2.03 from continuing operations, alongside a US$1 billion share repurchase authorization running through 2028. The combination of strong international Omnipod performance and a large, multi year buyback plan reflects management’s focus on recurring cash generation and capital returns. Now the focus shifts to how Insulet’s stronger third quarter profitability and...

79. ❖Nov 4, 10:06 PMnewsvia finnhub

    Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60% and $1 ...

    Insulet Corp (PODD) delivered nearly 20% revenue growth with 490 basis points of operating margin expansion, while guiding 2027 growth modestly below mid-teens amid new competition.

80. ❖Nov 4, 2:14 PMnewsvia finnhub

    What Insulet (PODD) Said on Its Q3 Earnings Call

    Insulet (NASDAQ:PODD) reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company’s plans and U.S. performance landed within its guidance range. President and Chief Executive Officer Ashley McEvoy

81. ❖Nov 4, 1:29 PMnewsvia finnhub

    Insulet Corporation Q3 2026 Earnings Call Summary

    Moby summary of Insulet Corporation's Q3 2026 earnings call

82. ❖Nov 4, 12:01 PMnewsvia finnhub

    Insulet (PODD) Q3 2026 Earnings Call Transcript

    Revenue beat guidance and the full-year outlook was narrowed upward.

83. ❖Nov 4, 10:21 AMnewsvia finnhub

    Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share

    Insulet stock jumps on strong Q3 results, beating estimates with $842M in revenue, raising its 2026 outlook, and launching a $1B buyback.

84. ❖Nov 4, 8:30 AMnewsvia finnhub

    Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

    While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

85. ❖Nov 4, 8:14 AMnewsvia finnhub

    Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript

    Insulet Corporation (PODD) Q3 2026 Earnings Call November 4, 2026 8:00 AM ESTCompany ParticipantsClare Trachtman - Vice President of Investor...

86. ❖Nov 4, 7:30 AMnewsvia finnhub

    Insulet (NASDAQ:PODD) posts better-than-expected sales in Q3 2026, stock soars

    Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 19.2% year on year to $842 million. Its non-GAAP profit of $1.99 per share was 25.4% above analysts’ consensus estimates.

87. ❖Nov 4, 7:10 AMnewsvia finnhub

    Insulet (PODD) Q3 Earnings and Revenues Surpass Estimates

    Insulet (PODD) delivered earnings and revenue surprises of +25.16% and +1.04%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

88. ❖Nov 4, 7:06 AMnewsvia finnhub

    Insulet: Q3 Earnings Snapshot

    (PODD) on Wednesday reported third-quarter net income of $141.The Acton, Massachusetts-based company said it had net income of $2.

89. ❖Nov 4, 7:00 AMnewsvia finnhub

    Insulet Reports Third Quarter 2026 Results

    ACTON, Mass., November 04, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026.

90. ❖Nov 4, 5:07 AMnewsvia finnhub

    Insulet Q3 2026 Earnings Call Transcript

    Insulet (NASDAQ:PODD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

91. ❖Nov 4, 5:06 AMnewsvia finnhub

    Conference call: Insulet Sees Q4 Sales $889.600M-$917.000M vs $900.481M Est

    Insulet (NASDAQ:PODD) sees Q4 sales of $889.600 million-$917.000 million vs $900.481 million analyst estimate.

92. ❖Nov 4, 3:14 AMnewsvia finnhub

    Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.46 Est; Raises FY2026 Sales Guidance from $3.250B-$3.304B to $3.277B-$3.304B vs $3.289B Est

    Insulet (NASDAQ:PODD) FY2026 expected to be more than $6.46 vs $6.46 Est. raises FY2026 sales outlook from $3.250 billion-$3.304 billion to $3.277 billion-$3.304 billion vs $3.289 billion estimate.

93. ❖Nov 4, 3:01 AMnewsvia finnhub

    Insulet Q3 Adj. EPS $1.99 Beats $1.59 Estimate, Sales $842.000M Beat $832.685M Estimate

    Insulet (NASDAQ:PODD) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $1.59 by 25.16 percent. This is a 60.48 percent increase over earnings of $1.24 per share from the same

94. ?Oct 16, 1:50 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is up 2.08% with 115 minutes remaining, which is a meaningful move suggesting real institutional flow. No news catalyst is present, but absence of news is not disqualifying — this could reflect anticipation of earnings, sector rotation into medical devices, or quiet accumulation. The macro context (elevated mortgage rates) is not directly relevant to PODD (insulin pump/diabetes device company), so no meaningful macro headwind applies here. With 115 minutes remaining there is reasonable time for continuation, but the move is already in the 2%+ range, meaning some profit-taking risk into the close is plausible. No reversal pattern is noted — price appears to be holding gains rather than fading. Overall, this is a modest momentum setup with no strong reason to fade, landing in the ordinary continuation bucket. Taking a slight lean toward continuation given bounded risk parameters and ample time remaining.

95. !Oct 16, 1:50 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    PODD is up 2.08% with 115 minutes remaining, which is a meaningful move suggesting real institutional flow. No news catalyst is present, but absence of news is not disqualifying — this could reflect anticipation of earnings, sector rotation into medical devices, or quiet accumulation. The macro context (elevated mortgage rates) is not directly relevant to PODD (insulin pump/diabetes device company), so no meaningful macro headwind applies here. With 115 minutes remaining there is reasonable time for continuation, but the move is already in the 2%+ range, meaning some profit-taking risk into the close is plausible. No reversal pattern is noted — price appears to be holding gains rather than fading. Overall, this is a modest momentum setup with no strong reason to fade, landing in the ordinary continuation bucket. Taking a slight lean toward continuation given bounded risk parameters and ample time remaining.

96. ?Oct 15, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

97. !Oct 15, 7:00 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

98. ?Oct 15, 7:00 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

99. ?Oct 14, 6:02 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    PODD (Insulet Corporation) is a medtech company with a strong market position in tubeless insulin pump delivery (OmniPod), and there are no company-specific negative catalysts visible in the available evidence — no guidance cuts, no accounting issues, and no adverse news headlines in the 30-day window. The 10.2% drawdown from the 30-day high appears technically driven rather than fundamentally justified. The primary headwind is the macro context: the 5-year forward inflation rate (T5YIFR) is running 1.9σ above its 24-month trend, which tends to pressure rate-sensitive and growth-oriented healthcare names like PODD through multiple compression, creating a modest but real overhang on near-term rebound potential.

100. ?Oct 14, 4:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

101. ?Oct 14, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

102. ?Oct 14, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

103. ?Oct 14, 3:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

104. ?Oct 14, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

105. ?Oct 14, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

106. ?Oct 14, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

107. ?Oct 14, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

108. ?Oct 14, 12:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

109. ?Oct 14, 12:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

110. ?Oct 14, 10:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD is down 10% from its 30-day high with no fundamental deterioration visible in recent 8-K filings (no guidance cuts, no going-concern language). However, two meaningful headwinds weigh on the thesis: earnings are 21 days away (a soft negative, uncertainty premium), and the macro environment is challenging with the 10Y yield at 5.24% (a structural headwind for a growth/duration-sensitive medtech name like PODD) and T5YIFR elevated 1.5σ above trend. The CFO filed a Form 4 "F" (tax withholding/share surrender, not an open-market sale cluster), sector health care is middling (rank 4/11, slight underperformance vs SPY over 30 days), and there is no insider cluster buy or unusual call flow to offset the headwinds. Net signal score is approximately -1 to 0, insufficient to support a buy above the 0.50 threshold.

111. ?Oct 14, 10:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corp) is a fundamentally sound medical device company in the diabetes care space, and the 10% dip from its 30-day high is moderate. However, the evidence is notably sparse: no news headlines, no meaningful SEC filing metrics, and no options flow data to diagnose the cause of the drop or confirm a recovery catalyst. The lone insider activity is a CFO Form 4 'F' (tax withholding/share surrender) filing — not a purchase — which is a mild negative signal on a dip. Earnings are 21 days away, placing this in the elevated-caution window where binary risk is real; consensus EPS of $1.65 provides a benchmark but no margin-of-safety context. The macro backdrop features a high 10Y yield (5.24%), negative sector 30-day relative strength vs. SPY, and a risk-off broad market day, all of which weigh against near-term recovery.

112. ?Oct 13, 10:30 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     PODD is down 1.60% today with no attributable headline catalyst, suggesting this is likely flow-driven or sector/macro-related selling. The move is modest — below the 2% threshold that would indicate strong conviction — which limits confidence in continuation. The macro context shows the T10Y3M spread elevated at 1.6σ above trend, which is mildly risk-off and could weigh on growth/med-tech names like PODD, providing a soft tailwind for the downside thesis. However, with 315 minutes remaining (essentially a full remaining session), there is ample time for either continuation or mean reversion. No news means we cannot confirm a fundamental driver, but per guidance this is not a disqualifier. The setup is borderline: a mild downmove, no clear catalyst, mildly supportive macro for further weakness, and plenty of time remaining. Assigning 0.5 — the minimum threshold — reflecting a lean toward continuation but with low conviction, driven primarily by the macro backdrop and the absence of a reversal signal.

113. ?Oct 12, 6:21 PMdecisionconsidered

     Agent 20 — SIR Price/Volume — buy

     [not executed — reserve_floor_or_cash] [cluster_break_up] After a sustained decline from $141.55 (2026-09-17) to a trough of $130.47 (2026-09-30), PODD formed a tight price cluster in the $130.47–$135.62 range from 2026-10-01 through 2026-10-09, with volume largely subdued (865K–3.3M, the elevated 10-01/10-02 prints reflecting panic/capitulation rather than distribution). Today's bar (2026-10-12) breaks cleanly above that cluster with a close of $139.81 — a +3.35% advance that recaptures the mid-September support zone — on 1.3M shares, broadly in line with ADV, which is healthy for a breakout (not exhaustion-volume, not feeble). The two-day capitulation spike on 2026-10-01 (3.3M) and 2026-10-02 (3.1M) at the lows, followed by a controlled drift higher on shrinking volume into 2026-10-09 (865K), is a textbook SIR accumulation sub-path ending in a cluster break; today's bar completes the pattern by clearing $135–$136 resistance on re-engagement volume. Risks: A failure to hold above the $135–$136 breakout level on a subsequent session, particularly if accompanied by volume expansion on the down-day, would invalidate the cluster_break_up read and suggest the today's move was a one-day overextension rather than genuine demand absorption. Additionally, the elevated 10Y-3M spread (0.99, +1.6σ) signals macro stress that could weigh on growth/health-care names if risk appetite deteriorates broadly.

114. ?Oct 12, 10:50 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     PODD is up 2.25% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike that might exhaust quickly. The move is meaningful but not extreme, leaving room for continuation. Macro context shows a positive yield curve signal (T10Y3M at 1.6σ above trend), which is modestly risk-positive but more relevant to financials than medical devices. With 295 minutes remaining there is ample time for the move to extend, which is supportive. No reversal signals or fade patterns are noted. The absence of news is not a disqualifier per the framework — the base case is mild continuation. However, without a clear catalyst or sector tailwind specifically for PODD, and given the macro context is sector-neutral to slightly irrelevant here, confidence is modest. Assigning 0.54 — slight lean toward continuation with no strong reason to expect a fade.

115. ?Oct 12, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     PODD (Insulet Corporation) is a medtech name in Health Care, a sector currently ranked 2nd of 11 by 30-day relative strength with meaningful outperformance vs. SPY (+3.29pts over 30 days). The 10% dip from the 30-day high does not appear to be driven by fundamental deterioration — the available SEC filings lack any disclosed guidance cuts, covenant issues, or going-concern language, and there are no adverse news headlines. The broader market tone today is constructive (SPY +0.88%, QQQ +1.70%), suggesting the pullback is idiosyncratic rather than macro-driven. However, with earnings 44 days away, there is a meaningful uncertainty premium, and the sector is actually outperforming, suggesting the drop is single-stock specific — a mild negative. The 10-year yield at 4.94% is a structural headwind for a growth/duration-sensitive medtech name. Net signal score: sector outperformance while stock drops (-1, idiosyncratic), high 10Y yield (-1), earnings in 15-30+ days but within uncertainty window (-1 for 44 days is borderline; scored as 0 since >30 days), no earnings within 30 days (+1), macro context neutral (+0, rates elevated but VIX low at 13th percentile). Net: approximately -1, which does not support a buy.

116. ▣Sep 10, 8:00 PMjournalstop

     Agent 5 — Dip Buyer (Evolving) closed long 11 @ $133.63 (-$138.65)

     intraday stop sweep

117. ❖Sep 9, 1:27 PMnewsvia finnhub

     Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

     Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

118. ❖Sep 8, 9:24 AMnewsvia finnhub

     Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

     PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.

119. ❖Sep 8, 9:00 AMnewsvia finnhub

     Artisan Sold Insulet (PODD) Due to Competition Concerns

     Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

120. ❖Sep 4, 11:30 AMnewsvia finnhub

     Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?

     Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

121. ❖Sep 4, 7:10 AMnewsvia finnhub

     Baron SMID Cap ETF Q2 2026 Portfolio Activity

     During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products.

122. ❖Sep 3, 8:39 PMnewsvia finnhub

     Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

     As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

123. ❖Sep 2, 4:11 PMnewsvia finnhub

     Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds

     Insulet stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market multiples currently point to the shares trading below what those models suggest, while the broader valuation score still comes through as a mixed signal rather than a clear bargain. The share price is down 57.0% over the past year, which puts recent trading well below where many investors may have entered the stock. Future adoption of Insulet's...

124. ❖Sep 2, 11:09 AMnewsvia finnhub

     Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks?

     Insulet (PODD) is back in focus after ongoing reminders about a securities class action lawsuit tied to alleged issues in its manufacturing controls and recent voluntary Medical Device Corrections disclosed in March and May 2026. At a share price of US$148.38, Insulet has seen short term resilience with a 7 day share price return of 3.73%. However, the 30 day share price return is down 10.26% and the 1 year total shareholder return has declined 56.98%, which points to fading momentum as...

125. ❖Sep 1, 8:47 AMnewsvia finnhub

     MiniMed submits new patch pump for FDA clearance

     The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.

126. ❖Aug 31, 12:35 PMnewsvia finnhub

     Uncover the latest developments among S&P500 stocks in today's session.

     Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

127. ❖Aug 29, 7:30 AMnewsvia finnhub

     Insulet Corporation: Strong Growth Meets A New Execution Problem

     Insulet Corporation delivered strong Q2 2026 results with 23.5% revenue growth, strong customer additions, and solid profitability. Click for more on PODD.

128. ❖Aug 27, 6:00 AMnewsvia finnhub

     Insulet (NASDAQ:PODD): Growth at a Reasonable Valuation

     Insulet Corp (PODD) fits the affordable growth screen: strong EPS and revenue growth, reasonable valuation, and overall solid profitability.

129. ❖Aug 26, 5:36 AMnewsvia finnhub

     FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

     The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

130. ❖Aug 24, 7:11 PMnewsvia finnhub

     The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

     Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

131. ❖Aug 24, 8:35 AMnewsvia finnhub

     These S&P500 stocks are moving in today's pre-market session

     Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.

132. ▢Aug 23, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 11 @ $146.23

133. ▣Aug 4, 8:00 PMjournalstop

     Agent 5 — Dip Buyer (Evolving) closed long 19 @ $131.21 (-$300.34)

     intraday stop sweep

134. ▣Jul 20, 8:00 PMjournaltarget

     Agent 4 — Dip Buyer (Frozen) closed long 7 @ $167.37 (+$198.80)

     Target hit: close $167.37 ≥ target $164.66

135. ▢Jun 30, 8:00 PMjournal

     Agent 7 — Day Trader opened long 18 @ $158.10

136. ▣Jun 30, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 18 @ $159.59 (+$26.91)

     EOD forced close — day trader never carries overnight

137. ▣Jun 21, 8:00 PMjournalstop

     Agent 8 — Dip Buyer (Peer-Aware) closed long 6 @ $139.54 (-$50.19)

     intraday stop sweep

138. ▢Jun 21, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 7 @ $138.97

139. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 19 @ $147.02

140. ▢May 18, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 6 @ $147.91